Tesaro (TSRO) PT Raised to $128 at RBC Capital

October 10, 2016 7:27 AM EDT
Get Alerts TSRO Hot Sheet
Price: $139.87 --0%

Rating Summary:
    13 Buy, 3 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 15 | New: 12
Trade TSRO Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

RBC Capital analyst Adnan Butt reiterated an Outperform rating and raised its price target on Tesaro (NASDAQ: TSRO) to $128.00 (from $122.00) following NOVA Phase 3 trial details.

Butt commented, "Details show biomarker/HRD-positive benefit is not driven by somatic BRCA patients alone, biomarker/HRD-negative population shows a stat sig benefit, which allows TSRO to file broadly for platinum sensitive ovarian cancer patients, the broadest addressable market and an upside scenario, and safety/tolerability differences could point to further PARP inhibitor separation. Niraparib is the PARP inhibitor to beat and there is no legitimate competitive threat near-term. PT to $128 from $122."

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $99.26 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

RBC Capital

Add Your Comment